Detalhe da pesquisa
1.
Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real-world genomic datasets.
Mol Oncol
; 17(2): 230-237, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36269676
2.
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study.
Lung Cancer
; 178: 166-171, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36868177
3.
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial.
Nat Med
; 29(10): 2577-2585, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37710001
4.
Retinol saturase promotes adipogenesis and is downregulated in obesity.
Proc Natl Acad Sci U S A
; 106(4): 1105-10, 2009 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-19139408
5.
Clinical Validation of Companion Diagnostics for the Selection of Patients with Non-Small Cell Lung Cancer Tumors Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutations for Treatment with Amivantamab.
J Mol Diagn
; 24(11): 1181-1188, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35963523
6.
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
J Clin Oncol
; 39(30): 3391-3402, 2021 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34339292
7.
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC.
Cancer Discov
; 10(8): 1194-1209, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32414908
8.
Erratum: Drug Discovery Approaches to Target Wnt Signaling in Cancer Stem Cells.
Oncotarget
; 9(78): 34856, 2018 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30410683
9.
p53 in human embryonal carcinoma: identification of a transferable, transcriptional repression domain in the N-terminal region of p53.
Oncogene
; 24(9): 1481-90, 2005 Feb 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-15674351
10.
Positive and negative regulation of deltaN-p63 promoter activity by p53 and deltaN-p63-alpha contributes to differential regulation of p53 target genes.
Oncogene
; 22(48): 7607-16, 2003 Oct 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-14576823
11.
Novel drug discovery opportunities for colorectal cancer.
Expert Opin Drug Discov
; 8(9): 1153-64, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23768167
12.
Drug discovery approaches to target Wnt signaling in cancer stem cells.
Oncotarget
; 1(7): 563-577, 2010 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-21317452
13.
Re-expression of GATA2 cooperates with peroxisome proliferator-activated receptor-gamma depletion to revert the adipocyte phenotype.
J Biol Chem
; 284(14): 9458-64, 2009 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-19136559
14.
A widely used retinoic acid receptor antagonist induces peroxisome proliferator-activated receptor-gamma activity.
Mol Pharmacol
; 71(5): 1251-7, 2007 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-17290005
15.
Rev-erbalpha, a heme sensor that coordinates metabolic and circadian pathways.
Science
; 318(5857): 1786-9, 2007 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-18006707
16.
Retinoid target gene activation during induced tumor cell differentiation: human embryonal carcinoma as a model.
J Nutr
; 133(1): 273S-276S, 2003 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-12514308